Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Alba Ginés"'
Autor:
Alba Ginés, Sara Bystrup, Vicenç Ruiz de Porras, Cristina Guardia, Eva Musulén, Anna Martínez-Cardús, José Luis Manzano, Laura Layos, Albert Abad, Eva Martínez-Balibrea
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0123830 (2015)
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplati
Externí odkaz:
https://doaj.org/article/db9b14ae152947aa823c7a183722175b
Autor:
Sara Bystrup, Manel Esteller, Vicenç Ruiz de Porras, Jose Luis Manzano, Catia Moutinho, Anna Martínez-Cardús, Cristina Buges, Albert Abad, Laura Layos, Alba Ginés, Eva Martinez-Balibrea
Publikováno v:
Molecular Cancer Therapeutics. 14:1767-1776
Oxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in the management of this malignancy. It is also considered for the treatment of pancreatic and gastric cancers. However, a major reason for t
Autor:
Jose Luis Manzano, Miquel Taron, Anna Martínez-Cardús, Raquel Malumbres, Eva Martinez-Balibrea, Eva Bandrés, Jesús García-Foncillas, Albert Abad, Alba Ginés
Publikováno v:
Molecular Cancer Therapeutics. 8:194-202
Oxaliplatin is a third-generation platinum agent used in colorectal cancer treatment. Oxaliplatin resistance acquisition is a complex process mainly based on alteration of genes and pathways involved in its mechanism of action. Therefore, our purpose
Autor:
Javier Sastre, Elisabet Guino, Enrique Aranda, Auxiliadora Gómez-España, I. Maestu, Jorge Aparicio, Eva Martinez-Balibrea, Albert Abad, Jose Luis Manzano, T. García, Eduardo Díaz-Rubio, Alba Ginés, Anna Martínez-Cardús
Publikováno v:
European Journal of Cancer. 44:1229-1237
We studied the role of TS ( 5'VNTR, 5'SNP and 3'UTR ), XRCC1-399, XPD-751, ERCC1-118 and XRCC3-241 genetic polymorphisms in tailoring fluroropyrimidine/oxaliplatin treatment. For this purpose, 110 XELOX (capecitabine/oxaliplatin)- or FUOX (fluorourac
Autor:
Albert Abad, Alba Ginés, Nouri Neamati, Eva Musulen, Anna Martínez-Cardús, Jose Luis Manzano, Eva Martinez-Balibrea, Carmen Plasencia, Rodrigo Aguilera
Publikováno v:
Molecular cancer therapeutics. 8(4)
We aimed to gain further understanding of the molecular mechanisms involved in oxaliplatin resistance in colorectal cancer by using a proteomic approach. A 5-fold oxaliplatin-resistant cell line, HTOXAR3, was compared with its parental cell line, HT2
Autor:
Albert Abad, Eva Martinez-Balibrea, Alba Ginés, Carmen Plasencia, Jose Luis Manzano, Enrique Aranda, Eva Musulen, Nouri Neamati, Anna Martínez-Cardús
Publikováno v:
International journal of cancer. 124(12)
Recently, the copper efflux transporters ATP7B and ATP7A have been implicated in the transport of and resistance to platinum drugs in breast and ovarian cancers. Because of the extensive use of oxaliplatin in colorectal cancer (CRC), we examined the
Autor:
Laura Layos, Anna Martínez-Cardús, Jose Luis Manzano, Vicenç Ruiz de Porras, Eva Martinez-Balibrea, Albert Abad, Alba Ginés, Sara Bystrup, Cristina Buges
Publikováno v:
Cancer Research. 75:5478-5478
Background: In previous work we have observed hyper-activation of the transcription factor (TF) NF-κB and an up-regulation of the Cyclin-dependent kinase 5 (CDK5) in human colorectal cancer cell lines with acquired resistance to oxaliplatin (OXA). M
Autor:
Albert Abad, Cristina Guardia, Alba Ginés, Eva Musulen, Eva Martinez-Balibrea, Anna Martínez-Cardús, Vicenç Ruiz de Porras, Laura Layos, Sara Bystrup, Jose Luis Manzano
Publikováno v:
PLoS ONE
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
PLoS ONE, Vol 10, Iss 5, p e0123830 (2015)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
PLoS ONE, Vol 10, Iss 5, p e0123830 (2015)
Ajuts: Beca bianual de la Fundació Olga Torres 2008-2009 Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work
Autor:
Jose Luis Manzano, Eva Musulen, Eva Martinez-Balibrea, Albert Abad, Anna Martínez-Cardús, Alba Ginés, Vicenç Ruiz de Porras, Laura Layos, Cristina Buges
Publikováno v:
Cancer Research. 74:3752-3752
Background/purpose: Despite remaining one of the most active drugs in the treatment of advanced colorectal cancer (aCRC), oxaliplatin (OXA) resistance still is a multifactorial and complex process to decipher. In a previous work we identified low lev
Autor:
Eva Martinez-Balibrea, Cristina Buges, Vicenç Ruiz de Porras, Laia Capdevila, Sara Cros, Albert Abad, Enric Carcereny, Alba Ginés, Anna Martinez Cardús
Publikováno v:
Journal of Clinical Oncology. 30:9129-9129
9129 Background: Morphine sulfate is the most widely used opioid in oncologic pain. There is a high variability in response between individuals. The objectives are to correlate the variability in response (R) and tolerability with polymorphisms withi